- Trials with a EudraCT protocol (138)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
138 result(s) found for: Pelvic tumor.
Displaying page 1 of 7.
EudraCT Number: 2008-007412-15 | Sponsor Protocol Number: CSET 2008/1443 | Start Date*: 2009-01-26 | |||||||||||
Sponsor Name:Institut Gustave Roussy | |||||||||||||
Full Title: Essai de phase III comparant la perfusion isolée pelvienne (PIP) avec du TNF-α 0,3 mg et du melphalan 1,5 mg/kg versus traitement standard dans les tumeurs pelviennes localement évoluées d’origine ... | |||||||||||||
Medical condition: Tumeur pelvienne localement évoluée d’origine gynécologique ou digestive | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003980-38 | Sponsor Protocol Number: ML 21800 | Start Date*: 2008-09-22 |
Sponsor Name:Roche Slovensko s.r.o. | ||
Full Title: An open label study of the effect of Xeloda and radiotherapy on pathological response rate in patients with locally advanced rectal cancer. | ||
Medical condition: Locally advanced rectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003381-40 | Sponsor Protocol Number: BED-PSMA-301 | Start Date*: 2020-06-22 | |||||||||||
Sponsor Name:Blue Earth Diagnostics Ireland Ltd. | |||||||||||||
Full Title: A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001864-30 | Sponsor Protocol Number: MIP-1404-201 | Start Date*: 2012-09-25 | |||||||||||
Sponsor Name:Molecular Insight Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men with High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (E... | |||||||||||||
Medical condition: Prostate Cancer within prostate gland and metastatic prostate cancer in regional lymph nodes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) CZ (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002833-39 | Sponsor Protocol Number: CHUBX2017/52 | Start Date*: 2018-12-12 |
Sponsor Name:CHU DE BORDEAUX | ||
Full Title: A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment for locally recurrent rectal cancer (GRECCAR – PRODIGE ... | ||
Medical condition: Recurrent rectal cancer after local excision | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002429-37 | Sponsor Protocol Number: NSGO-EC-9501 Amendment 2 | Start Date*: 2004-11-17 |
Sponsor Name:Nordic Society for Gynecologic Oncology | ||
Full Title: A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2. | ||
Medical condition: Endometrial cancer stage I-III radically operated with high-risk factors (high-grade and deep myometrial infiltration, or serous or clear cell histology) that will receive adjuvant treatment with r... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004310-18 | Sponsor Protocol Number: SPL-01-001 | Start Date*: 2019-10-07 | |||||||||||
Sponsor Name:Saving Patients' Lives Medical B.V. | |||||||||||||
Full Title: A confirmatory, prospective, open-label, single-arm, reader-blinded multi-centre phase 3 study to assess the diagnostic accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and unen... | |||||||||||||
Medical condition: newly-diagnosed prostate cancer (PCA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023081-52 | Sponsor Protocol Number: ENGOT-EN2-DGCG | Start Date*: 2011-01-25 | ||||||||||||||||
Sponsor Name:Danish Gynaecological Cancer Group (DGCG) | ||||||||||||||||||
Full Title: A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer. | ||||||||||||||||||
Medical condition: Endometrial cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) SE (Completed) BE (Completed) FI (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) IT (Completed) NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002854-19 | Sponsor Protocol Number: S58827 | Start Date*: 2017-08-03 |
Sponsor Name:UZ Leuven | ||
Full Title: Neoadjuvant degarelix +/- apalutamide (ARN-509) followed by radical prostatectomy for intermediate and high-risk prostate cancer: a randomized, placebo-controlled trial. | ||
Medical condition: Prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003152-37 | Sponsor Protocol Number: MK3475-A18/ENGOT-cx11/GOG-3047 | Start Date*: 2020-05-28 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | |||||||||||||
Full Title: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047) | |||||||||||||
Medical condition: High-risk locally advanced cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001533-34 | Sponsor Protocol Number: 36/2007/O/Sper | Start Date*: 2007-04-17 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: A Phase II Study of Panitumumab 5-Fluorouracil and Oxaliplatin in combination with pelvic radiotherapy as treatment of resectable and locally advanced rectal cancer (StarPan Study ヨ STAR 02) | |||||||||||||
Medical condition: rectal carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002325-18 | Sponsor Protocol Number: CATARTIC | Start Date*: 2021-09-28 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTI... | |||||||||||||
Medical condition: Localy advanced low-risk rectal cancer, placed at less then 15 cm form the anal verge and staged as cT = 2 and cN0 or cT1-3 cN1 (TNM classification 8th edition), without evidence of distant metasta... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001206-29 | Sponsor Protocol Number: ShorTrip | Start Date*: 2021-07-22 | |||||||||||
Sponsor Name:Fondazione GONO | |||||||||||||
Full Title: ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer. | |||||||||||||
Medical condition: Locally advanced rectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005255-87 | Sponsor Protocol Number: 2014-13 | Start Date*: 2016-05-04 |
Sponsor Name:Assistance Publique Hôpitaux de MARSEILLE | ||
Full Title: Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study. | ||
Medical condition: Patients with intermediate-risk gastrointestinal stromal tumor presenting a high Genomic Grade Index | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003102-40 | Sponsor Protocol Number: M17CPF | Start Date*: 2018-11-01 | |||||||||||
Sponsor Name:NKI-AVL | |||||||||||||
Full Title: Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility | |||||||||||||
Medical condition: women ≥18 and ≤ 40 years with FIGO stage Ib1 cervical carcinoma with tumor measuring ≥ 2 cm and ≤ 4 cm on physical examination and imaging | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003927-12 | Sponsor Protocol Number: CHUBX2012/28 | Start Date*: 2014-03-03 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Development of an innovative Gallium 68 radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT imaging of neuro-endocrine tumors and preliminary clinical evaluation | |||||||||||||
Medical condition: neuroendocrine tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000566-38 | Sponsor Protocol Number: GETUG-AFU_23_/_UC-0160/1202 | Start Date*: 2014-07-23 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse | |||||||||||||
Medical condition: localized prostate cancer with high-risk features of relapse | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Prematurely Ended) BE (Trial now transitioned) DE (Completed) PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000802-30 | Sponsor Protocol Number: ML18522 | Start Date*: 2005-09-15 | |||||||||||
Sponsor Name:ROCHE | |||||||||||||
Full Title: Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer. | |||||||||||||
Medical condition: Patients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022037-29 | Sponsor Protocol Number: AFU-GETUG 20/0310 | Start Date*: 2011-01-31 | |||||||||||
Sponsor Name:FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer) | |||||||||||||
Full Title: Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of r... | |||||||||||||
Medical condition: PROSTATIC ADENOCARCINOMA WITH HIGH RISK OF RECURRENCE. | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male | ||||||||||||
Trial protocol: FR (Trial now transitioned) SK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002717-35 | Sponsor Protocol Number: P170920J | Start Date*: 2018-12-13 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemoradiotherapy for locally advanced resectable rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE) | |||||||||||||
Medical condition: Adults ≥ 18 years with middle or low locally advanced resectable rectal carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
